Monday, November 16, 2026

Larimar Narrows Q3 Loss; Completes BLA Submission For Nomlabofusp In Friedreich's Ataxia

Published: 11/16/2026. Larimar completed its rolling BLA submission to the U.S. Food and Drug Administration (FDA), seeking accelerated approval of nomlabofusp for adults and pediatric patients with Friedreich's ataxia. The application uses frataxin (FXN) as a potential novel surrogate endpoint.

BLA submission acceptance is expected in early 2027. An open-label study safety update is anticipated in the first quarter of 2027, followed by a potential U.S. approval in mid-2027, subject to FDA review. 

 If approved, Larimar is targeting a U.S. commercial launch in the third quarter of 2027. The company also expects to obtain and monetize a Rare Pediatric Disease Priority Review Voucher in mid-2027, if nomlabofusp receives approval.